WO2003066055A1 - Quinoline derivatives as npy antagonists - Google Patents

Quinoline derivatives as npy antagonists Download PDF

Info

Publication number
WO2003066055A1
WO2003066055A1 PCT/EP2003/000777 EP0300777W WO03066055A1 WO 2003066055 A1 WO2003066055 A1 WO 2003066055A1 EP 0300777 W EP0300777 W EP 0300777W WO 03066055 A1 WO03066055 A1 WO 03066055A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyrrolidin
quinolin
iodo
alkyl
Prior art date
Application number
PCT/EP2003/000777
Other languages
English (en)
French (fr)
Inventor
Patrizio Mattei
Werner Mueller
Werner Neidhart
Matthias Heinrich Nettekoven
Philippe Pflieger
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to AU2003205679A priority Critical patent/AU2003205679B2/en
Priority to MXPA04007502A priority patent/MXPA04007502A/es
Priority to EP03702533A priority patent/EP1474145B1/en
Priority to KR1020047012036A priority patent/KR100659428B1/ko
Priority to BR0307441-2A priority patent/BR0307441A/pt
Priority to ES03702533T priority patent/ES2304498T3/es
Priority to CA002473181A priority patent/CA2473181A1/en
Priority to JP2003565479A priority patent/JP4216196B2/ja
Priority to DE60320529T priority patent/DE60320529T2/de
Publication of WO2003066055A1 publication Critical patent/WO2003066055A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention is concerned with novel quinoline derivatives useful as neuropeptide Y (NPY) receptor ligands, particularly neuropeptide Y (NPY) antagonists.
  • the invention is concerned especially with compounds of formula
  • R 1 and R 2 are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyL aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylalkylcarbonyl, carbocyclyl, carbocyclylalkyl, amino, aIkyl-S0 2 -, aryl-SO 2 -, heterocyclyI-SO 2 - or amino-SO 2 - or R 1 and R 2 together with the N atom to which they are attached form a 5- to 10- membered heterocyclic ring which optionally comprises a second heteroatom selected from nitrogen or oxygen and, wherein the heterocyclyc ring is optionally substituted with one or more substituents
  • R 4 is hydrogen, halogen, heterocyclyl, amino or alkyl
  • A is a 5 to 7-membered saturated heterocyclic ring comprising the nitrogen atom which is attached to the quinoline ring and optionally a second heteroatom which is selected from oxygen, sulfur or nitrogen and, wherein the ring A is optionally substituted by one to three substituents independently selected from alkyl, alkoxy, hydroxy, amino, acetylamino, cyano, hydroxyalkyl, alkoxyalkyl, cycloalkylalkoxy and cycloalkylalkoxyalkyl;
  • the compounds of formula I and their pharmaceutically acceptable salts and esters are novel and have valuable pharmacological properties. They are neuropeptide ligands, for example neuropeptide receptor antagonists and in particular, they are selective neuropeptides Y Y5 receptor antagonists.
  • Neuropetide Y is a 36 amino acid peptide that is widely distributed in the central and peripheral nervous systems. This peptide mediates a number of physiological effects through its various receptor subtypes. Studies in animals have shown that neuropeptide Y is a powerful stimulus of food intake, and it has been demonstrated that activation of neuropeptide Y Y5 receptors results in hyperphagia and decreased thermogenesis. Therefore compounds that antagonise neuropetide Y at the Y5 receptor subtype represent an approach to the treatment of eating disorders such as obesity and hyperphagia.
  • NPY neuropeptide Y
  • ⁇ PY neuropeptide Y
  • ⁇ PY neuropeptide Y
  • Reduction and long-term maintenance of body weight can also have beneficial consequences on con associated risk factors such as arthritis, cardiovascular diseases, diabetes and renal failure.
  • the compounds of formula I, their salts and esters can be used in the prophylaxis or treatment of of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
  • Objects of the present invention are the compounds of formula I and their aforementioned salts and esters per se and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments comprising the said compounds, their pharmaceutically acceptable salts and esters, the use of the said compounds, salts and esters for the prophylaxis and/or therapy of illnesses, especially in the treatment or prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders such as hyperphagia and particularly obesity, and the use of the said compounds, salts and esters for the production of medicaments for the treatment or prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
  • alkyl signifies a straight-chain or branched- chain alkyl group with 1 to 8 carbon atoms, preferably a straight or branched- chain alkyl group with 1 to 6 carbon atoms and particularly preferred a straight or branched- chain alkyl group with 1 to 4 carbon atoms
  • straight- chain and branched -Cs alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.
  • cycloalkyl signifies a cycloalkyl ring with 3 to 8 carbon atoms and preferably a cycloalkyl ring with 3 to 6 carbon atoms.
  • Examples of C 3 -Cs cycloalkyl are cyclopropyl, methyl-cyclopropyl, dimethylcyclopropyl, cyclobutyl, methyl- cyclobutyl, cyclopentyl, methyl-cyclopentyl, cyclohexyl, methyl- cyclohexyl, dimethyl- cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclopropyl and particularly cyclopentyl.
  • alkoxy signifies a group of the formula alkyl- O- in which the term “alkyl” has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec. butoxy and tertbutoxy, 2- hydroxyethoxy, 2-methoxyethoxypreferably methoxy and ethoxy and most preferred methoxy.
  • aryl signifies a phenyl or naphthyl group, preferably a phenyl group which optionally carries one or more, particularly one to three substituents each independently selected from halogen, trifluoromethyl, amino, alkyl, alkoxy, aryloxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylendioxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkyaminocarbonyl, dialkylaminocarbonyl, hydroxy, nitrol and the like.
  • Preferred substituents of aryl are independently selected from halogen, trifluoromethyl, alkyl, alkoxy, cyano and nitro.
  • Examples of aryl are phenyl, cyanophenyl, methoxyphenyl, fluorophenyl and methylphenyl.
  • aralkyl signifies an alkyl or cycloalkyl group as previously defined, which is substituted with one or more, preferably one or two, particularly preferred one aryl group and, wherein the term aryl is defined as before.
  • Examples are benzyl, benzyl substituted with hydroxy, alkoxy or halogen, preferably fluorine.
  • heterocyclyl signifies a saturated, partially unsaturated or aromatic 4- to 10-membered heterocycle which contains one or more, preferably one ore two hetero atoms selected from nitrogen, oxygen and sulfur, wherein oxygen and particularly nitrogen are preferred. If desired, it can be substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo, alkoxyalkyl, hydroxyalkyl etc. and/or on a secondary nitrogen atom (i.e.
  • alkyl, cycloalkyl, aralk ⁇ xycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary nitrogen atom (i.e. N-) by oxido, with halogen, alkyl, cycloalkyl and alkoxy being preferred.
  • heterocyclyl groups examples include pyridinyl, furyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, 3,4-dihydro-lH- isoquinolinyl, thiophenyl and azepanyl, wherein each of these rings can be optionally substituted by one or more, preferably one substituent independently selected from alkyl and halogen.
  • Particularly preferred are pyrrolidinyl, pyridinyl, furyl, thiophenyl and chloro-pyridinyl.
  • carbocyclyl alone or in combination, signifies partially unsaturated 4- to 10-membered carbocyclic ring, wherein optionally one or more carbon atoms are substituted by halogen, alkyl, cycloalkyl, alkoxy, oxo, aryl, with alkyl being preferred.
  • An examples of carbocyclyl is indanyl.
  • amino signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, -NH 2) methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidinyl and piperidino. Particularly preferred primary amino.
  • cycloalkylalkyl signifies an alkyl group which is substituted with one or more, preferably one cycloalkyl group and, wherein the terms alkyl and cycloalkyl have the previously given significance.
  • cycloalkylalkylcarbonyl alone or in combination, signifies a cycloalkylalkyl-C(O)- group, wherein cycloalkylalkyl is defined as before.
  • cycloalkylalkoxy alone or in combination, signifies an alkoxy group which is substituted with one or more, preferably one cycloalkyl group and, wherein the terms alkoxy and cycloalkyl have the previously given significance.
  • cycloalkylalkoxyalkyl alone or in combination, signifies an alkyl group which is substituted with one or more, preferably one cycloalkylalkoxy group and, wherein the terms alkyl and cycloalkylalkoxy have the previously given significance.
  • heterocyclylalkylcarbonyl alone or in combination, signifies a heterocyclylalkyl-C(O)- group, wherein heterocyclylalkyl is defined as before.
  • aralkylcarbonyl alone or in combination, signifies an aralkyl-C(O)- group, wherein aralkyl is defined as before.
  • alkylcarbonyl alone or in combination, signifies an alkyl-(CO)- group, wherein the term alkyl has the previously given significance.
  • cycloalkylcarbonyl alone or in combination, signifies a c cloalkyl-(CO)- group, wherein the term cycloalkyl has the previously given significance.
  • arylcarbonyl alone or in combination, signifies an aryl-(CO)- group, wherein the term aryl has the previously given significance.
  • alkoxyalkyl signifies an alkyl group which is substituted with one or more, preferably one alkoxy group and, wherein the terms alkyl and alkoxy have the previously given significance.
  • hydroxyalkyl signifies an alkyl group which is substituted with one or more, preferably one hydroxy group and, wherein the terms alkyl and hydroxy have the previously given significance.
  • heterocyclylalkyl alone or in combination, signifies an alkyl group which is substituted with one or more, preferably one heterocyclyl group and, wherein the terms alkyl and heterocyclyl have the previously given significance.
  • heterocyclylcarbonyl alone or in combination, signifies a heterocyclyl- (CO)- group, wherein the term heterocyclyl has the previously given significance.
  • Carbocyclylalkyl alone or in combination, signifies an alkyl group which is substituted with one or more, preferably one carbocyclyl group and, wherein the terms alkyl and carbocyclyl have the previously given significance.
  • halogen signifies fluorine, chlorine, bromine or iodine and preferably fluorine, chlorine or bromine and particularly chlorine.
  • cyano alone or in combination, signifies a -CN group.
  • nitro alone or in combination, signifies a -N0 2 group.
  • hydroxy alone or in combination, signifies a -OH group.
  • carbonyl refers to a group of formula -C(O)-.
  • Examples of pharmaceutically acceptable salts of the compounds of formula I are salts with physiologically compatible mineral acids such hydrochloric acid, sulfuric acid or phosphoric acid; or with organic acids such as methanesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid, salicylic acid and oxalic acid. Preferred are the hydrochloride salts.
  • the compounds of formula I with free carboxy groups can also form salts with physiologically compatible bases. Examples of such salts are alkali metal, alkali earth metal, ammonium and alkylammonium salts such as the Na, K, Ca or tertramethylammonium salt.
  • the compound of formula I can also be present in the form of zwitterions.
  • the compounds of formula I can also be solvated, e.g. hydrated.
  • the solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration).
  • pharmaceutically acceptable salts also includes pharmaceutically usable solvates.
  • esters of the compounds of formula I means that compounds of general formula (I) may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo.
  • examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters.
  • any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo are within the scope of this invention.
  • the COOH groups of compounds according to formula I can be esterified.
  • the alkyl and aralkyl esters are examples of suitable esters.
  • the methyl, ethyl, propyl, butyl and benzyl esters are preferred esters.
  • the methyl and ethyl esters are especially preferred.
  • Further examples of pharmaceutically usable esters are compounds of formula I, wherein the hydroxy groups can be esterified. Examples of such esters are formate, acetate, propionate, butyrate, isobutyrate, valerate, 2-methylbutyrate, isovalerate and N,N-dimethylaminoacetate.
  • Preferred esters are acetate and N,N- dimethylaminoacetate.
  • lipase inhibitor refers to compounds which are capable of inhibiting the action of lipases, for example gastric and pancreatic lipases.
  • lipases for example gastric and pancreatic lipases.
  • orlistat and lipstatin as described in U.S. Patent No. 4,598,089 are potent inhibitor of lipases.
  • Lipstatin is a natural product of microbial origin, and orlistat is the result of a hydrogenation of lipstatin.
  • Other lipase inhibitors include a class of compound commonly referred to as panclicins. Panclicins are analogues of orlistat (Mutoh et al, 1994).
  • lipase inhibitor refers also to polymer bound lipase inhibitors for example described in International Patent Application WO99/34786 (Geltex Pharmaceuticals Inc.). These polymers are characterized in that they have been substituted with one or more groups that inhibit lipases.
  • lipase inhibitor also comprises pharmaceutically acceptable salts of these compounds.
  • lipase inhibitor preferably refers to orlistat.
  • Orlistat is a known compound useful for the control or prevention of obesity and hyperlipidemia. See, U.S. Patent No. 4,598,089, issued July 1, 1986, which also discloses processes for making orlistat and U.S. Patent No. 6,004,996, which discloses appropriate pharmaceutical compositions. Further suitable pharmaceutical compositions are described for example in International Patent Applications WO 00/09122 and WO 00/09123. Additional processes for the preparation of orlistat are disclosed in European Patent Applications Publication Nos. 185,359, 189,577, 443,449, and 524,495. Orlistat is preferably orally administered from 60 to 720 mg per day in divided doses two to three times per day.
  • a lipase inhibitor is administered to a subject, preferably in divided doses two or, particularly, three times per day.
  • the subject is preferably an obese or overweight human, i.e. a human with a body mass index of 25 or greater.
  • the lipase inhibitor be administered within about one or two hours of ingestion of a meal containing fat.
  • treatment be administered to a human who has a strong family history of obesity and has obtained a body mass index of 25 or greater.
  • Orlistat can be administered to humans in conventional oral compositions, such as, tablets, coated tablets, hard and soft gelatin capsules, emulsions or suspensions.
  • carriers which can be used for tablets, coated tablets, dragees and hard gelatin capsules are lactose, other sugars and sugar alcohols like sorbitol, mannitol, maltodextrin, or other fillers; surfactants like sodium lauryle sulfate, Brij 96, or Tween 80; disintegrants like sodium starch glycolate, maize starch or derivatives thereof; polymers like povidone, crospovidone; talc; stearic acid or its salts and the like.
  • Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like.
  • the pharmaceutical preparations can contain preserving agents, solubilizers, stabilizing agents, wetting agents, emulsifying agents, sweetening agents, coloring agents, flavoring agents, salts for varying the osmotic pressure, buffers, coating agents and antioxidants. They can also contain still other therapeutically valuable substances.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods known in the pharmaceutical art. Preferably, orlistat is administered according to the formulation shown in the Examples and in U.S. Patent No. 6,004,996, respectively.
  • the compounds of formula I can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
  • R 3 is attached at the 2-position and R 4 is attached at the 6-position.
  • R 1 and R 2 are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl, cycloalkylcarbonyl, aryl, aralkyl, arylcarbonyl, alkoxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, carbocyclyl, carbocyclylalkyl, amino, alkyl-SO 2 -, aryl-SO 2 -, heterocyclyl-SO 2 - or amino-SO 2 - or R 1 and R 2 together with the N atom to which they are attached form a 5- to 10- membered heterocyclic ring which optionally comprises a second heteroatom selected from nitrogen or oxygen and, wherein the heterocyclyc ring is optionally substituted with one or more substituents independently selected from alkyl and alkoxy; and
  • A is a 5 to 7-membered saturated heterocyclic ring comprising the nitrogen atom which is attached to the quinoline ring and optionally a second heteroatom which is selected from oxygen, sulfur or nitrogen and, wherein the ring A is optionally substituted by one to three substituents independently selected from alkyl, alkoxy, hydroxy, amino, acetylamino, cyano, hydroxyalkyl and alkoxyalkyl.
  • Particularly preferred are compounds according to formula I, wherein R 4 is hydrogen.
  • Another preferred aspect of the present invention are compounds according to formula I, wherein R 4 is amino, particularly pyrrolidinyl.
  • A is pyrrolidine or azepane optionally substituted with alkyl, alkoxyalkyl or hydroxyalkyl.
  • A is pyrrolidine or azepane optionally substituted with alkyl, alkoxy, alkoxyalkyl or hydroxyalkyl.
  • Particularly preferred are compounds of formula I, wherein A is pyrrolidine optionally substituted with hydroxymethyl, methoxymethyl, methoxy or ethoxy.
  • R 1 and R 2 are compounds according to formula I, wherein one of R 1 and R 2 is hydrogen or alkyl and the other is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl, cycloalkylcarbonyl, phenyl, naphthyl, phenylalkyl, naphthylalkyl, phenylcarbonyl, alkoxyalkyl, hydroxyalkyl, thiophenyl, pyridinyl, furyl, thiophenylalkyl, pyridinylalkyl, f ⁇ irylalkyl, thiophenylcarbonyl, pyridinylcarbonyl, furylalkyl, indanyl, carbocyclylalkyl, amino, alkyl-S0 2 -, aryl-SO 2 -, thiophenyl-S0 2 -, pyridinyl-SO 2 -,
  • R 1 and R 2 are hydrogen or methyl and the other is independently selected from alkylcarbonyl, cycloalkylcarbonyl, cyanophen l, alkoxybenyl, cyanophenylcarbonyl, fluorophenylcarbonyl, thiophenylalkyl, pyridinylcarbonyl, furylcarbonyl, alkyl-SO 2 -, pyridyl-S0 2 -, pyridinyl and cycloalkylcarbonyl.
  • a particularly preferred aspect of the present invention are compounds of formula I, wherein one of R 1 and R 2 is hydrogen or methyl and the other is independently selected from alkylcarbonyl, cycloalkylcarbonyl, cyanophenyl, alkoxybenyl, cyanophenylcarbonyl, fluorophenylcarbonyl, thiophenylalkyl, pyridinylcarbonyl, furylcarbonyl, alkyl-SO 2 - and pyridyl-S0 2 -.
  • furan-2-carboxylic acid (2-methyl-4-pyrrolidin-l-yl-quinolin-7-yl)-amide
  • furan-2-carboxylic acid (2,6-dimethyl-4-pyrrolidin-l-yl-quinolin-7-yl)-amide
  • Pd(OAc) 2 as catalyst, BINAP (2,2 bis(dipenylphosphino)-l,l-binaphthyl) or Xanthphos as chelating phosphine ligand, or with other Palladium catalysts such as SK-CC01-A (commercial from Solvias), and with NaOtBu or cesium carbonate as a base - in a solvent such as toluene or dioxane, and at elevated temperature (S. L. Buchwald in: J Am. Chem. Soc. 1996, p. 10333, Ace. Chem Res. 1998, p 805, Org Lett., 2000,2, 1104).
  • the couplings can achieved via an Ullman-type reaction with, for example Cu(I) chloride, or Cu(I) iodide in a solvent such as dioxane or DMF, in analogy to a methods described by J.A. Ragan ( Synthesis 1998, pl599) and more recently by S.L. Buchwald (J. Am. Chem. Soc, 2001, 7727).
  • compounds of formula I can be obtained from lb, according to scheme 2, by an appropriate sequence of alkylation reactions with corresponding alkyl halogenides in the presence of a base such as sodium hydride in THF or DMSO or by using Buchwald- type Pd catalyzed C/N bond formation reactions or Ullaman-type coupling with aryl and heteroaryl amines as discussed above - for the cases were R ⁇ R 2 equals aryl and heteroaryl).
  • a base such as sodium hydride in THF or DMSO
  • R 1 , R 2 equaling alkylcarbonyl, arylcarbonyl , heterocylycarbonyl aryl-, heteroaryl- or alkyl sulfonyl
  • R 1 , R 2 equaling alkylcarbonyl, arylcarbonyl , heterocylycarbonyl aryl-, heteroaryl- or alkyl sulfonyl
  • acylation or sulfonation
  • Hal in scheme 2 means chloro, bromo or iodo.
  • a further alternative consists of having the corresponding substituents already incorporated in the scaffold on preparation of the compounds of formula I according to the schemes shown below.
  • R 4 having the meaning as defined above can be prepared from lc (scheme 3) in a Pd catalyzed Buchwald couplings (from corresponding amines or N- heterocycles), or from R 4" M (M means Sn(Bu) 3 , or B(OH) 2 or Li andMg salts) in Stille,- Suzuki- or Negishi-type cross-couplings essentially as known in the literature, or R IS already incorporated in the scaffold according to the reaction sequences shown below.
  • substitutents as R 4 can be introduced according to scheme 4 on reaction of compounds of formula Id with an correponding amine or N- heterocyle and in a suitable solvent such as THF or DMSO (Hal means F, Cl, Br or I), or via Pd catalysed bond forming reactions as above to give Ie (Hal means Cl, Br or I).
  • a suitable solvent such as THF or DMSO
  • Hal means F, Cl, Br or I a suitable solvent
  • Pd catalysed bond forming reactions as above to give Ie Hal means Cl, Br or I.
  • the conversion of le to lb is accomplished by reduction with for example SnCl 2 as reducing agent, essentially as known in the literature.
  • An alternative sequence consists of transformation of Id in If by, for example SnCl 2 reduction followed by Palladium catalyzed cross-coupling reactions as discussed above.
  • Transformation to the corresponding chloro quinoline derivatives of formula VI is performed on treatment with POCI 3 under reflux, a standard method known in the literature. Subsequent reaction with corresponding amines as defined above, either using a large excess of amine without solvent or on reaction with a 2-fold access in a suited solvent such as ⁇ -methyl pyrrolidone, xylol, ethanol or THF, optionally in the presence of catalytic amounts of ⁇ al and with pyridine as a base, gives compounds of formula Ial.
  • R 3 is hydrogen or alkyl
  • R' is methyl or ethyl
  • R' means NH 2 ; R is defined as before;
  • R' means NR 1 R 2 , R 4 means Hal;
  • R' means N0 2 , R 4 means Hal;
  • R' means N0 2 , R 4 as defined before;
  • R' means NH 2 , R 4 means Hal;
  • R 3 is NH 2 , alkylamino or dialkylamino
  • R' is methyl or ethyl
  • a further method to prepare compounds of general formula Ia2 comprises condensation of anilines of formula Ilia with malonic esters to give compounds of formula IX. Subsequent ring closure provides the 2,4-dihydroxyquinolines of general formula X. Subsequent chlorination with POCl 3 gives then the 2,4-dichloro-quinolines of formula XI which can be selectively transformed to compounds of type Ia2 by sequential substitution reactions with the corresponding amines in analogy to known reactions in the literature.
  • the compounds Ib2 - If2 can be prepared accordingly from Illb-f as outlined above.
  • R 3 is NH 2 , alkylamino, dialkyl amino or chloro
  • R', R" is methyl or ethyl
  • the conversion of a compound of formula I into a pharmaceutically acceptable salt can be carried out by treatment of such a compound with an inorganic acid, for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid etc., or with an organic acid, such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p- toluenesulfonic acid.
  • an inorganic acid for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid etc.
  • an organic acid such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p- toluenesulfonic acid.
  • the conversion of compounds of formula I into pharmaceutically usable esters or amides can be carried out e.g. by treatment of suited amino or hydroxyl groups present in the molecules with an carboxylic acid such as acetic acid, with a condensating reagent such as benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) or N,N-dicylohexylcarbodiimide (DCC) to produce the carboxylic ester or carboxylic amide.
  • a condensating reagent such as benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) or N,N-dicylohexylcarbodiimide (DCC)
  • an object of the invention are compounds described above for the production of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the NPY receptor, particularly for the production of medicaments for the prophylaxis and therapy of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
  • an object of the invention are pharmaceutical compositions comprising a compound of formula I described above and a therapeutically inert carrier.
  • An object of the invention is also the use of the compounds described above for the production of medicaments, particularly for the treatment and prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
  • a further object of the invention comprises compounds which are manufactured according to one of the described processes.
  • a further object of the invention is a method for the treatment and prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity whereby an effective amount of a compound described above is administered.
  • a method of treatment of obesity in a human in need of such treatment which comprises administration to the human a therapeutically effective amount of a compound according to formula I and a therapeutically effective amount of a lipase inhibitor, particularly preferred, wherein the lipase inhibitor is orlistat. Also subject of the present invention is the mentioned method, wherein the administration is simultaneous, separate or sequential.
  • a further preferred embodiment of the present invention is the use of a compound of the formula I in the manufacture of a medicament for the treatment and prevention of obesity in a patient who is also receiving treatment with a lipase inhibitor, particularly preferred, wherein the lipase inhibitor is orlistat.
  • a preferred process for the preparation of a compound according to formula I comprises one of the following reactions:
  • R 1 to R 4 and A are defined as before and Hal means chloro, bromo or iodo.
  • this reaction is performed by an Pd catalysed coupling reaction under Buchwald conditions.
  • Pd catalysed coupling reaction under Buchwald conditions.
  • the above reaction in the presence of Cu(I) salts, preferably Cu(I)chloride or Cu(I)iodide.
  • R 1 to R 4 and A are defined as before and Hal means chloro, bromo or iodo.
  • R 1 to R 4 and A are defined as in claim 1 and Hal means chloro, bromo or iodo.
  • an object of the invention are compounds described above for the production of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the NPY receptor, particularly for the production of medicaments for the prophylaxis and therapy of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
  • a pharmaceutical composition comprising a compound of formula I described above and a therapeutically inert carrier. Preferred is this composition comprising further a therapeutically effective amount of a lipase inhibitor. Particularly preferred is the above composition, wherein the lipase inhibitor is orlistat.
  • An object of the invention is also the use of the compounds described above for the production of medicaments, particularly for the treatment and prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
  • a further object of the invention comprises compounds which are manufactured according to one of the described processes.
  • a further object of the invention is a method for the treatment and prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity whereby an effective amount of a compound described above is administered.
  • a method of treatment of obesity in a human in need of such treatment which comprises administration to the human a therapeutically effective amount of a compound according to formula I and a therapeutically effective amount of a lipase inhibitor, particularly preferred, wherein the lipase inhibitor is orlistat. Also subject of the present invention is the mentioned method, wherein the administration is simultaneous, separate or sequential.
  • a further preferred embodiment of the present invention is the use of a compound of the formula I in the manufacture of a medicament for the treatment and prevention of obesity in a patient who is also receiving treatment with a lipase inhibitor, particularly preferred, wherein the lipase inhibitor is orlistat.
  • the full-length cDNA encoding the mouse NPY5 (mNPY5) receptor was amplified from mouse brain cDNA using specific primers, designed based on the published sequence, and Pfu DNA-Polymerase (Stratagene). The amplification product was subcloned into the mammalian expression vector pcDNA3 using Eco RI and Xhol restriction sites. Positive clones were sequenced and one clone, encoding the published sequence was selected for generation of stable cell clones.
  • HEK293 Human embryonic kidney 293 (HEK293) (ATCC No. CRL-1573) cells were transfected with 10 ⁇ g mNPY5 DNA using the lipofectamine reagent (Gibco BRL) according to the manufacturer's instruction. Two days after transfection, geneticin selection ( 1 mg/ml) was initiated and several stable clones were isolated. One clone was further used for pharmacological characterization.
  • HEK293 Human embryonic kidney 293 cells (HEK293), expressing recombinant mouse NPY5-receptor (mNPY5) were broken by three freeze/thawing cycles in hypotonic Tris buffer (5 mM, pH 7.4, 1 mM MgCl 2 ), homogenized and centrifuged at 72,000 x g for 15 min. The pellet was washed twice with 75 mM Tris buffer, pH 7.4, containing 25 mM
  • Radioligand competition binding assays were performed in 250 ⁇ l 25 mM Hepes buffer (pH 7.4, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 1 % bovine serum albumine, and 0.01 %
  • Preferred compounds as described above have IC 50 values below 1000 nM; more preferred compounds have IC 50 values below 100 nM, particularly below 10 nM. Most preferred compounds have IC 50 values below 1 nM.
  • the compounds of formula I and their pharmaceutically usable salts, solvates and esters can be used as medicaments (e.g. in the form of pharmaceutical preparations).
  • the pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories).
  • the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).
  • the compounds of formula I and their pharmaceutically usable salts, solvates and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragees and hard gelatin capsules.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragees and hard gelatin capsules.
  • Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
  • Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
  • Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
  • Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
  • the pharmaceutical preparations can contain preservatives, solubilizers, viscosity- increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the compounds of formula I and their pharmaceutically usable salts, solvates and esters can be used for the prophylaxis and treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
  • the dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • Example 8 In analogy to example 1, on reaction of 7-iodo-2-methyl-4-pyrrolidin-l-yl-quinoline with morpholine there was obtained: 2-Methyl-7-morpholin-4-yl-4-pyrrolidin-l-yl-quinoline a brown viscous oil. ISP mass spectrum, m/e: 298.4 (M+l calculated for C 18 H 23 N 3 ⁇ : 298).
  • Example 10 a In analogy to example la), on reaction of (R)-7-iodo-4-(2-methoxymethyl-pyrrolidin- l-yl)-2-methyl-quinoline with cyclopropylmethylamine there was obtained: (R)- cyclopropylmethyl-[4-(2-methoxymethyl-pyrrolidin-l-yl)-2-methyl-quinolin-7-yl] -amine an amorphous brown solid.
  • Example 11 a In analogy to example la), on reaction of (R,S)-7-iodo-2-methyl-4-(2-methyl- pyrrolidin-1-yl) -quinoline with cyclopropylmethylamine there was obtained: (R,S)- cyclopropylmethyl-[2-methyl-4-(2-methyl-pyrrolidin-l-yl)-quinolin-7-yl] -amine an amorphous brown solid.
  • Example 12 a In analogy to example la), on reaction 7-iodo-4-pyrrolidin-l-yl-quinoline with cyclopropylmethylamine there was obtained: cyclopropylmethyl-(4-pyrrolidin-l-yl- quinolin-7-yl)-amine a viscous oil. ISP mass spectrum, m/e: 268.4 (M+l calculated for C ⁇ 7 H 2 ⁇ N 3 : 268).
  • Example 13 In analogy to example 1, on reaction of 7-iodo-2-methyl-4-pyrrolidin-l-yl-quinoline with 3-aminopyridine there was obtained: (2-methyl-4-pyrrolidin-l-yl-quinolin-7-yl)-pyridin- 3-yl- amine as brown solid.
  • Example 25 a In analogy to example la), on reaction of 4-azepan-l-yl-7-iodo-2-methyl-quinoline with 4-trifluoromethylbenzylamine there was obtained (4-azepan-l-yl-2-methyl-quinolin- 7-yl)-(4-trifluoromethyl-benzyl)-amine a light brown solid.
  • Example 63 In analogy to example 47, on reaction of (S)-[l-(7-iodo-2-methyl-quinolin-4-yl)- pyrrolidin-2-yl] -methanol, product of example 53b), with furylamide there was obtained: (S)- furan-2-carboxylic acid [4-(2-hydroxymethyl-pyrrolidin-l-yl)-2-methyl-quinolin-7- yl] -amide as light yellow. ISP mass spectrum, m/e: 352.4 (M+l calculated for C 20 H 2 ⁇ N 3 ⁇ 3 : 352).
  • Example 80 In analogy to example 64, on reaction of (S)- [ l-(7-iodo-2-methyl-quinolin-4-yl)- pyrrolidin-2-yl] -methanol, product of example 53b), with cyclopropyl carboxamide there was obtained: (S)-cyclopropanecarboxylic acid [4-(2-hydroxymethyl-pyrrolidin-l-yl)-2- methyl-quinolin-7-yl] -amide as an amorphous light brown solid. ISP mass spectrum, m/e: 326.3 (M+l calculated for C 19 H 23 N 3 O 2 : 326).
  • Example 81 In analogy to example 64, on reaction of (S)- [ l-(7-iodo-2-methyl-quinolin-4-yl)- pyrrolidin-2-yl] -methanol, product of example 53b), with cyclopropyl carboxamide there was obtained: (S)-cyclopropanecarboxy
  • Example 106 In analogy to example 64, on reaction (S)-7-iodo-4-(2-methoxymethyl-pyrrolidin-l-yl)-2- methyl- quinoline, product of example 100b), with propionamide there was obtained: (S)- N-[4-(2-methoxymefhyl-pyrrolidin-l-yl)-2-methyl-quinolin-7-yl] -propionamide as an off-white solid.
  • Example 107 In analogy to example 64, on reaction (S)-7-iodo-4-(2-methoxymethyl-pyrrolidin-l-yl)-2- methyl-quinoline, product of example 100b), with 4-cyanobenzamide there was obtained: (S) -4-cyano-N- [4- (2-methoxymethyl-pyrrolidin- 1 -yl) -2-methyl-quinolin-7-yl] - benzamide as an light brown amorphous solid. ISP mass spectrum, m/e: 401.5 (M+l calculated for C 24 H 24 N 4 0 2 : 401).
  • Example 108 a In analogy to example 1, on reaction (S)-4-(2-ethoxymethyl-pyrrolidin-l-yl)-7-iodo-2- methyl- quinoline hydrochloride with 4-fluoroaniline and conversion of the free base to the hydrochloride, there was obtained: (S)-[4-(2-ethoxymethyl-pyrrolidin-l-yl)-2-methyl- quinolin-7-yl] -(4-fluoro-phenyl)-amine hydrochloride as an off-white solid.
  • Example 113 a In analogy to example 1, on reaction (S) 4-(2-cyclopropylmethoxymethyl-pyrrolidin-l- yl)-7-iodo-2-methyl-quinoline hydrochloride, product of example 112b), with 3- aminopyridine and conversion of the free base to the hydrochloride, there was obtained: (S)-[4-(2-cyclopropylmethoxymethyl-pyrrolidin-l-yl)-2-methyl-quinolin-7-yl]-pyridin-3- yl-amine hydrochloride as a brown foam.
  • Example 114 a In analogy to example 64, on reaction of (R)-4-(3-efhoxy-pyrrolidin-l-yl)-7-iodo-2- methyl-quinoline hydrochloride with 4-cyanobenzamide there was obtained: (R)-4-cyano- N- [4- (3-ethoxy-pyrrolidin-l-yl)-2-methyl-quinolin-7-yl] -benzamide as a yellow solid.
  • Example 115 a In analogy to example 64, on reaction of (S)-4-(3-cyclopropylmethoxy-pyrrolidin-l-yl)- 7-iodo-2-methyl-quinoline with nicotinamide there was obtained: (S)-N- [4-(3- cyclopropylmethoxy-pyrrolidin-l-yl)-2-methyl-quinolin-7-yl] -nicotinamide as a light yellow solid. ISP mass spectrum, m/e: 403.5 (M+l calculated for C 24 H 26 N 4 0 2 : 403).
  • a compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
  • a compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:
  • Example C Tablets comprising the following ingredients can be manufactured in a conventional manner:
  • Capsules comprising the following ingredients can be manufactured in a conventional manner:
  • Injection solutions can have the following composition:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
PCT/EP2003/000777 2002-02-04 2003-01-27 Quinoline derivatives as npy antagonists WO2003066055A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2003205679A AU2003205679B2 (en) 2002-02-04 2003-01-27 Quinoline derivatives as NPY antagonists
MXPA04007502A MXPA04007502A (es) 2002-02-04 2003-01-27 Derivados de quinolina como antagonistas de neuropeptido y (npy).
EP03702533A EP1474145B1 (en) 2002-02-04 2003-01-27 Quinoline derivatives as npy antagonists
KR1020047012036A KR100659428B1 (ko) 2002-02-04 2003-01-27 Ｎｐｙ 길항제로서의 퀴놀린 유도체
BR0307441-2A BR0307441A (pt) 2002-02-04 2003-01-27 Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade
ES03702533T ES2304498T3 (es) 2002-02-04 2003-01-27 Derivados de quinolina como antagonistas de npy.
CA002473181A CA2473181A1 (en) 2002-02-04 2003-01-27 Quinoline derivatives as npy antagonists
JP2003565479A JP4216196B2 (ja) 2002-02-04 2003-01-27 Ｎｐｙアンタゴニストとしてのキノリン誘導体
DE60320529T DE60320529T2 (de) 2002-02-04 2003-01-27 Chinolinderivate als npy antagonisten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02001967 2002-02-04
EP02001967.5 2002-02-04

Publications (1)

Publication Number Publication Date
WO2003066055A1 true WO2003066055A1 (en) 2003-08-14

Family

ID=27635782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/000777 WO2003066055A1 (en) 2002-02-04 2003-01-27 Quinoline derivatives as npy antagonists

Country Status (19)

Country Link
US (1) US6696467B2 (zh)
EP (1) EP1474145B1 (zh)
JP (1) JP4216196B2 (zh)
KR (1) KR100659428B1 (zh)
CN (1) CN100383124C (zh)
AR (1) AR038249A1 (zh)
AT (1) ATE392897T1 (zh)
AU (1) AU2003205679B2 (zh)
BR (1) BR0307441A (zh)
CA (1) CA2473181A1 (zh)
DE (1) DE60320529T2 (zh)
ES (1) ES2304498T3 (zh)
MX (1) MXPA04007502A (zh)
PE (1) PE20040120A1 (zh)
PL (1) PL372295A1 (zh)
RU (1) RU2298002C2 (zh)
TW (1) TW200400032A (zh)
UY (1) UY27646A1 (zh)
WO (1) WO2003066055A1 (zh)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511615A (ja) * 2003-11-19 2007-05-10 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
EP1934205A1 (en) * 2005-10-05 2008-06-25 Merck Frosst Canada Ltd. Substituted quinolines as inhibitors of leukotriene biosynthesis
WO2010056865A1 (en) * 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2017087608A1 (en) * 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10399976B2 (en) 2014-02-03 2019-09-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11001583B2 (en) 2014-11-05 2021-05-11 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
US11495746B2 (en) 2017-05-12 2022-11-08 Dottikon Es Holding Ag Indane derivatives and their use in organic electronics

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP2004110367A (ja) * 2002-09-18 2004-04-08 Hitachi Ltd 記憶装置システムの制御方法、記憶制御装置、および記憶装置システム
US7317025B2 (en) 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
WO2008141077A1 (en) * 2007-05-10 2008-11-20 Janssen Pharmaceutica N.V. Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives
HUE034298T2 (en) * 2007-05-17 2018-02-28 Helperby Therapeutics Ltd Use of 4- (Pyrrolidin-1-yl) quinoline derivatives to kill clinically latent microorganisms
IN2012DN00471A (zh) * 2009-06-29 2015-06-05 Agios Pharmaceuticals Inc
AU2011336875B2 (en) * 2010-12-03 2016-09-01 Corteva Agriscience Llc Processes for the preparation of enamines
RU2612959C2 (ru) 2011-02-18 2017-03-14 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи Аминоиндановые соединения и их применение при лечении боли
CA2839703A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
MY157429A (en) 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014028675A1 (en) 2012-08-15 2014-02-20 Endo Pharmaceuticals Inc. Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
HRP20221279T1 (hr) 2016-07-14 2022-12-23 Crinetics Pharmaceuticals, Inc. Modulatori somatostatina i njihove uporabe
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
AU2018319016B2 (en) * 2017-08-17 2023-08-31 Ikena Oncology, Inc. AHR inhibitors and uses thereof
HUE059184T2 (hu) * 2018-01-17 2022-10-28 Crinetics Pharmaceuticals Inc Szomatosztatin modulátorok elõállításának folyamata
RU2702648C1 (ru) * 2019-07-11 2019-10-09 федеральное государственное автономное образовательное учреждение высшего образования «Южный федеральный университет» 5,7-Ди(трет-бутил)-2-(4,7-дихлор-8-метил-5-нитрохинолин-2-ил)-4-нитро-1,3-трополон, обладающий цитотоксической активностью
AU2021341936A1 (en) 2020-09-09 2023-05-25 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
WO1996037474A1 (en) * 1995-05-26 1996-11-28 Warner-Lambert Company Sulfonylquinolines as neuropeptide y1 antagonists
WO2002020488A2 (en) * 2000-09-06 2002-03-14 F. Hoffmann-La Roche Ag Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
WO2002094789A1 (en) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
CA2133620A1 (en) * 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
PT1105122E (pt) 1998-08-14 2005-08-31 Hoffmann La Roche Composicoes farmaceuticas que contem inibidores de lipase
JP3761783B2 (ja) 1998-08-14 2006-03-29 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤とキトサンを含む製薬学的組成物
DE10064105A1 (de) * 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
WO1996037474A1 (en) * 1995-05-26 1996-11-28 Warner-Lambert Company Sulfonylquinolines as neuropeptide y1 antagonists
WO2002020488A2 (en) * 2000-09-06 2002-03-14 F. Hoffmann-La Roche Ag Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
WO2002094789A1 (en) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4768628B2 (ja) * 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
KR101099849B1 (ko) 2003-11-19 2011-12-28 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
JP2007511615A (ja) * 2003-11-19 2007-05-10 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP1934205A4 (en) * 2005-10-05 2010-06-02 Merck Frosst Canada Ltd SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUCOTRIENE BIOSYNTHESIS
EP1934205A1 (en) * 2005-10-05 2008-06-25 Merck Frosst Canada Ltd. Substituted quinolines as inhibitors of leukotriene biosynthesis
WO2010056865A1 (en) * 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
US8664399B2 (en) 2008-11-14 2014-03-04 Gilead Sciences, Inc. Substituted heterocyclic compounds as ion channel modulators
US8865739B2 (en) 2008-11-14 2014-10-21 Gilead Sciences, Inc. Substituted heterocyclic compounds as ion channel modulators
US11535614B2 (en) 2014-02-03 2022-12-27 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10399976B2 (en) 2014-02-03 2019-09-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10807980B2 (en) 2014-02-03 2020-10-20 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US11001583B2 (en) 2014-11-05 2021-05-11 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10829448B2 (en) 2015-08-05 2020-11-10 Vitae Pharmaceuticals, Llc Substituted benzoimidazoles as modulators of ROR-γ
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
WO2017087608A1 (en) * 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US11495746B2 (en) 2017-05-12 2022-11-08 Dottikon Es Holding Ag Indane derivatives and their use in organic electronics
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma

Also Published As

Publication number Publication date
JP2005523901A (ja) 2005-08-11
BR0307441A (pt) 2005-01-04
PE20040120A1 (es) 2004-03-06
MXPA04007502A (es) 2004-11-10
CA2473181A1 (en) 2003-08-14
US6696467B2 (en) 2004-02-24
AU2003205679A1 (en) 2003-09-02
KR20040081484A (ko) 2004-09-21
TW200400032A (en) 2004-01-01
KR100659428B1 (ko) 2006-12-19
US20030153553A1 (en) 2003-08-14
PL372295A1 (en) 2005-07-11
ES2304498T3 (es) 2008-10-16
EP1474145B1 (en) 2008-04-23
RU2298002C2 (ru) 2007-04-27
JP4216196B2 (ja) 2009-01-28
ATE392897T1 (de) 2008-05-15
RU2004126936A (ru) 2005-10-10
DE60320529T2 (de) 2009-06-10
AU2003205679B2 (en) 2006-06-29
CN100383124C (zh) 2008-04-23
DE60320529D1 (de) 2008-06-05
EP1474145A1 (en) 2004-11-10
AR038249A1 (es) 2005-01-05
CN1627945A (zh) 2005-06-15
UY27646A1 (es) 2003-08-29

Similar Documents

Publication Publication Date Title
US6696467B2 (en) Quinoline derivatives
US6818767B2 (en) Quinoline derivatives
JP3095521B2 (ja) ピペラジン誘導体
JP4187652B2 (ja) ニューロペプチドｙアンタゴニストとしてのキノリン誘導体
US20020052356A1 (en) Neuropeptide Y antagonists
JP5069119B2 (ja) 血管内皮成長因子（ｖｅｇｆ）受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア
AU2003281346B2 (en) Quinazoline derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2473181

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003205679

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003702533

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007502

Country of ref document: MX

Ref document number: 372295

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2003565479

Country of ref document: JP

Ref document number: 20038032805

Country of ref document: CN

Ref document number: 1020047012036

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004126936

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2003702533

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003205679

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2003702533

Country of ref document: EP